{"id":"https://openalex.org/W2904414844","doi":"https://doi.org/10.1089/humc.2018.29037.gam","title":"Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies","display_name":"Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies","publication_year":2018,"publication_date":"2018-12-01","ids":{"openalex":"https://openalex.org/W2904414844","doi":"https://doi.org/10.1089/humc.2018.29037.gam","mag":"2904414844","pmid":"https://pubmed.ncbi.nlm.nih.gov/30547692","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6312046"},"language":"en","primary_location":{"id":"doi:10.1089/humc.2018.29037.gam","doi":"https://doi.org/10.1089/humc.2018.29037.gam","is_oa":true,"landing_page_url":"https://doi.org/10.1089/humc.2018.29037.gam","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/humc.2018.29037.gam","source":{"id":"https://openalex.org/S2764519212","display_name":"Human Gene Therapy Clinical Development","issn_l":"2324-8637","issn":["2324-8637","2324-8645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Gene Therapy Clinical Development","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.liebertpub.com/doi/pdf/10.1089/humc.2018.29037.gam","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056411961","display_name":"Gbolahan Amusa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Gbolahan Amusa","raw_affiliation_strings":["Equity Research Department, Chardan, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Equity Research Department, Chardan, New York, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084458782","display_name":"Taylor Feehley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Taylor Feehley","raw_affiliation_strings":["Equity Research Department, Chardan, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Equity Research Department, Chardan, New York, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049916336","display_name":"J. Kipchirchir Bitok","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Kipchirchir Bitok","raw_affiliation_strings":["Equity Research Department, Chardan, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Equity Research Department, Chardan, New York, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087196636","display_name":"Geulah Livshits","orcid":"https://orcid.org/0000-0002-3835-7377","observed_orcids":["https://orcid.org/0000-0002-3835-7377"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geulah Livshits","raw_affiliation_strings":["Equity Research Department, Chardan, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Equity Research Department, Chardan, New York, New York","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076008565","display_name":"Natalya Gertsik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Natalya Gertsik","raw_affiliation_strings":["Equity Research Department, Chardan, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Equity Research Department, Chardan, New York, New York","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5056411961"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.19040867,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"29","issue":"4","first_page":"179","last_page":"187"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12675","display_name":"Financial Reporting and Valuation Research","score":0.9556000232696533,"subfield":{"id":"https://openalex.org/subfields/1408","display_name":"Strategy and Management"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12675","display_name":"Financial Reporting and Valuation Research","score":0.9556000232696533,"subfield":{"id":"https://openalex.org/subfields/1408","display_name":"Strategy and Management"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.010700000450015068,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.006200000178068876,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/firm-valuation","display_name":"business valuation","score":0.7900000214576721},{"id":"https://openalex.org/keywords/in-vivo-gene-therapy","display_name":"in vivo gene therapy","score":0.9279999732971191},{"id":"https://openalex.org/keywords/aav9","display_name":"AAV9","score":0.8330000042915344},{"id":"https://openalex.org/keywords/breakthrough-innovation","display_name":"breakthrough innovation","score":0.7099999785423279},{"id":"https://openalex.org/keywords/market-capitalization","display_name":"market capitalization","score":0.6660000085830688},{"id":"https://openalex.org/keywords/mergers-and-acquisitions","display_name":"mergers and acquisitions","score":0.8799999952316284}],"concepts":[{"id":"https://openalex.org/C111599444","wikidata":"https://www.wikidata.org/wiki/Q213901","display_name":"Genetic enhancement","level":3,"score":0.5527384281158447},{"id":"https://openalex.org/C186027771","wikidata":"https://www.wikidata.org/wiki/Q4008379","display_name":"Valuation (finance)","level":2,"score":0.5515515804290771},{"id":"https://openalex.org/C2779137862","wikidata":"https://www.wikidata.org/wiki/Q425951","display_name":"Capitalization","level":2,"score":0.5314862728118896},{"id":"https://openalex.org/C193445137","wikidata":"https://www.wikidata.org/wiki/Q471719","display_name":"Market capitalization","level":4,"score":0.4527651071548462},{"id":"https://openalex.org/C2777526511","wikidata":"https://www.wikidata.org/wiki/Q691543","display_name":"Pace","level":2,"score":0.4217957854270935},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.41108250617980957},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.3865513205528259},{"id":"https://openalex.org/C2780299701","wikidata":"https://www.wikidata.org/wiki/Q475000","display_name":"Stock market","level":3,"score":0.3464829921722412},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.2307201325893402},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16247838735580444},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.10525757074356079},{"id":"https://openalex.org/C13280743","wikidata":"https://www.wikidata.org/wiki/Q131089","display_name":"Geodesy","level":1,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C2780762169","wikidata":"https://www.wikidata.org/wiki/Q5905368","display_name":"Horse","level":2,"score":0.0},{"id":"https://openalex.org/C205649164","wikidata":"https://www.wikidata.org/wiki/Q1071","display_name":"Geography","level":0,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D005069","descriptor_name":"Evaluation Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015316","descriptor_name":"Genetic Therapy","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D015316","descriptor_name":"Genetic Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D015316","descriptor_name":"Genetic Therapy","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1089/humc.2018.29037.gam","doi":"https://doi.org/10.1089/humc.2018.29037.gam","is_oa":true,"landing_page_url":"https://doi.org/10.1089/humc.2018.29037.gam","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/humc.2018.29037.gam","source":{"id":"https://openalex.org/S2764519212","display_name":"Human Gene Therapy Clinical Development","issn_l":"2324-8637","issn":["2324-8637","2324-8645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Gene Therapy Clinical Development","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5287725","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6312046","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6312046","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6312046","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hum Gene Ther Clin Dev","raw_type":"Text"},{"id":"pmid:30547692","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30547692","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human gene therapy. Clinical development","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1089/humc.2018.29037.gam","doi":"https://doi.org/10.1089/humc.2018.29037.gam","is_oa":true,"landing_page_url":"https://doi.org/10.1089/humc.2018.29037.gam","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/humc.2018.29037.gam","source":{"id":"https://openalex.org/S2764519212","display_name":"Human Gene Therapy Clinical Development","issn_l":"2324-8637","issn":["2324-8637","2324-8645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Gene Therapy Clinical Development","raw_type":"journal-article"},"sustainable_development_goals":[],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/9","display_name":"Industry, innovation and infrastructure","score":0.6299999952316284}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2904414844.pdf","grobid_xml":"https://content.openalex.org/works/W2904414844.grobid-xml"},"referenced_works_count":4,"referenced_works":["https://openalex.org/W2104697841","https://openalex.org/W2746053108","https://openalex.org/W2746285890","https://openalex.org/W2765253110"],"related_works":["https://openalex.org/W4244206764","https://openalex.org/W3148427842","https://openalex.org/W6941326944","https://openalex.org/W2303370173","https://openalex.org/W4388730576","https://openalex.org/W2236290332","https://openalex.org/W2063330735","https://openalex.org/W1983930729","https://openalex.org/W2035609155","https://openalex.org/W4311339595"],"abstract_inverted_index":{"The":[0],"era":[1],"of":[2,26,96,117,128,159,169,210,261],"gene":[3,28,51,99,134,160,183,223,243],"therapy":[4,29,52,100,135,161,184,224,244],"has":[5,141],"begun.":[6],"In":[7],"recent":[8,104],"years,":[9],"potentially":[10],"breakthrough":[11,211],"datasets":[12],"and":[13,107,172,250],"rapidly":[14],"expanding":[15],"company":[16,170],"pipelines":[17],"have":[18,56,177,216,253],"begun":[19],"to":[20,71,203],"overshadow":[21],"the":[22,27,39,87,94,97,103,115,151,157,166,199,208,220,229,259],"unfulfilled":[23],"promise":[24],"characteristic":[25],"sector":[30],"in":[31,38,44,49,64,77,86,129,150,156,181,221,231,237,241,257],"decades":[32],"prior.":[33],"One":[34],"barometer":[35],"for":[36,93,146],"progress":[37],"space":[40,101],"can":[41],"be":[42],"seen":[43],"stock":[45],"markets,":[46],"where":[47],"NASDAQ-listed":[48],"vivo":[50,130,182,222,242],"companies":[53,60,73,245],"we":[54,214],"follow":[55],"increased":[57],"from":[58],"4":[59],"with":[61,74],"$1.9":[62],"billion":[63,76,126],"market":[65,78],"capitalization":[66,79],"on":[67,80,144,207,240],"January":[68],"31,":[69,82],"2014,":[70],"24":[72],"$30.5":[75],"October":[81],"2018.":[83],"For":[84],"many":[85,143],"financial":[88],"community,":[89],"a":[90,110,232],"tangible":[91],"signal":[92,111],"emergence":[95],"broader":[98,217],"is":[102,228],"notable":[105],"mergers":[106],"acquisitions":[108],"activity,":[109],"that":[112,190,213,252,269],"previously":[113],"heralded":[114],"arrival":[116],"blockbuster":[118],"biotechnologies":[119],"like":[120],"monoclonal":[121],"antibodies.":[122],"Notably,":[123],"Novartis'":[124],"$8.7":[125],"acquisition":[127],"adeno-associated":[131],"virus":[132],"9-based":[133],"player,":[136],"AveXis,":[137],"earlier":[138],"this":[139,238],"year":[140],"focused":[142],"looking":[145],"new":[147],"investment":[148],"opportunities":[149],"space,":[152],"thereby":[153],"increasing":[154],"interest":[155],"valuation":[158,171,209,263],"companies.":[162],"This":[163,226],"perspective":[164],"discusses":[165],"theoretical":[167],"underpinnings":[168],"explains":[173],"why":[174],"traditional":[175,262],"approaches":[176,249,264],"limitations":[178,260],"when":[179],"valuing":[180],"companies,":[185],"which":[186],"produce":[187],"single":[188],"treatments":[189],"may":[191,270],"achieve":[192],"durable":[193],"or":[194],"curative":[195],"benefits.":[196],"We":[197],"use":[198],"AveXis":[200],"case":[201],"study":[202],"illustrate":[204],"certain":[205],"points":[206],"innovation":[212],"think":[215],"applicability":[218],"throughout":[219],"space.":[225],"publication":[227],"first":[230],"three-part":[233],"series.":[234],"Future":[235],"discussions":[236],"series":[239],"will":[246],"explore":[247],"real-world":[248],"considerations":[251],"already":[254],"proven":[255],"successful":[256],"mitigating":[258],"as":[265,267],"well":[266],"those":[268],"soon":[271],"emerge.":[272]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-12-22T00:00:00"}